Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT02845219
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT02827708
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT02773381
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3183
- Registration Number
- NCT02692716
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1201
- Registration Number
- NCT02648204
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1864
- Registration Number
- NCT02607865
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 113
- Registration Number
- NCT02557620
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 706
- Registration Number
- NCT02461589
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 957
- Registration Number
- NCT02453711
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rotherham, United Kingdom
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 397
- Registration Number
- NCT02305381
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Presov, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.